The quantitative examination is a well-known technique which can be used in amalgamation with other serological markers for calculating the HBV-DNA. Nucleic-acid-amplification technologies for-example the Polymerase-Chain-Reaction (PCR) can ensure serum and plasma to calculate the amount of HBV-DNA. (Heid et al.
, 1996; Higuchi et al., 1993; Saldanha et al., 2001). To attain maximum sensitivity and wide-range, COBAS® AmpliPrep/COBAS® TaqMan® HBV Test, v2.0 uses PCR technology, for the recognition of HBV viral-load quantitatively in EDTA and coagulated-blood.
The CAP /CTM HBV Test, v2.0 is a nucleic-acid-amplification test for the quantitative testing of Hepatitis-B-Virus (HBV) DNA in human-blood. The CAP/CTM HBV Test, v2.0 has two chief processes:• Specimen-preparation for the separation of HBV DNA.• Real-time-PCR amplification of target-DNA and discovery of cleaved dual-labeled oligo-nucleotide testing probe-specific to the target.?The CAP/CTM HBV Test, v2.
0 contains following key steps.• To manage automated specimen.• Automated Real-Time-PCR amplification.• Detecting the HBV target DNA.
• Measurement of HBV viral load.The Master-Mix reagent is utilized in CAP/CTM HBV-Test v2. It consists of primer pairs and probes particularly for both HBV DNA and HBV Quantitative Standard (QS) DNA. Equivalent quantitation of all genotypes of Hepatitis B is ensured by the Master-Mix reagent.
